Sold as Teveten. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Eprosartan Mesylate (sold as Teveten), first approved Dec 22, 1997, with 1 new use approved and 0 published complete response letters.
| Dec 22, 1997 | TevetenNDA 20738 ยท New molecular entity | Abbvie | 15 | Discontinued |
| Nov 16, 2011 | Eprosartan MesylateANDA 202012 | Pharmobedient | 3 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Abbvie